Business Wire

Ipsen announces new clinical data to be presented at ISPRM 2018 demonstrating commitment to neurotoxin research

Del

Regulatory News:

Ipsen (Euronext: IPN; ADR: IPSEY) today announced that its neurotoxin portfolio will be the subject of 13 abstracts at the 12th International Society of Physical and Rehabilitation Medicine World Congress. The meeting will be held in Paris, July 8-12, 2018.

The 13 abstracts will present neuroscience data that advances knowledge in physical and rehabilitation medicine including clinical outcomes linked to Ipsen’s portfolio in adult spasticity (upper and lower limbs), pediatric spasticity, and in cervical dystonia. In addition, an international survey investigating the burden of spasticity on patients and their caregivers will be presented, as well as real-world data that supports better understanding of current clinical practices.

Alexandre Lebeaut, MD, Executive Vice-President, R&D, Chief Scientific Officer, Ipsen said: “Ipsen will have its strongest ever neuroscience presence at ISPRM 2018, demonstrating our strong focus on advancing the boundaries of neurotoxin research and our long-term commitment to patients and the neuroscience community, notably through medical education programs and symposia. We will also disclose new data from the first-ever recombinant botulinum neurotoxin to be administered to humans, an area where we have the ambition to advance and unlock the potential of this innovative technology platform.”

Prof. Lynne Turner-Stokes, [Cicely Saunders Institute, King’s College London, UK] added: “The results of the large observational ULIS-III study, which aims to assess real-life clinical practice will be the subject of an oral presentation. This study demonstrated that pain reduction is an important and achievable primary treatment goal in some patients suffering with spasticity.”

Oral presentations:

  • Abstract ISPR8-2524 – FP16 Neuro-Orthopedics and Spasticity - Part II, Amphitheatre Bleu Wednesday 11th July 17.40 – 17.50
    • Botulinum Toxin A in Upper Limb Spasticity Management: Baseline Data from the Upper Limb International Spasticity (ULIS)-III Study
    • Presenting author: Lynne Turner-Stokes
  • Abstract ISPR8-2530 – FP16 Neuro-Orthopedics and Spasticity - Part II, Amphitheatre Bleu Wednesday 11th July 17.50 – 18.00
    • Relief of Spasticity-Related Pain with Botulinum Neurotoxin-A (BoNT-A) in Real Life Practice. Post-Hoc Analysis from a Large International Cohort Series
    • Presenting author: Lynne Turner-Stokes

Posters

  • Abstract ISPR8-1217 – A7.02 Rehabilitation Addressing to Specific Issues – Spasticity Management, Exhibition Area, 9th–12th July
    • Impact of Spasticity and Botulinum Toxin-A Injections on the Daily Life of Patients and their Caregivers: Results from an International Online Survey
    • Presenting author: Manuel Murie Fernandez
  • Abstract ISPR8-2146 – D3.03 Education and Training in Rehabilitation – Continuous Medical Education and Professional Development, Exhibition Area, 9th–12th July
    • Botulinum Neurotoxin-A Usage and Training in Cervical Dystonia & Spastic Paresis: First Results from the Ixcellence® Network Survey
    • Presenting author: Luis Jorge Jacinto
  • Abstract ISPR8-2147 – D3.03 Education and Training in Rehabilitation – Continuous Medical Education and Professional Development, Exhibition Area, 9th–12th July
    • Improving Management Practices of Cervical Dystonia and Spastic Paresis: 5 Years’ Experience of Ixcellence® Network, an Innovative International Educational Program
    • Presenting author: Luis Jorge Jacinto
  • Abstract ISPR8-2514 – A7.02 Rehabilitation Addressing to Specific Issues – Spasticity Management, Exhibition Area, 9th–12th July
    • Simultaneous Upper and Lower Limb AbobotulinumtoxinA Injections and Guided Self-Rehabilitation Contracts in Spastic Hemiparesis: Baseline Data from the ENGAGE Study
    • Presenting author: Jean-Michel Gracies
  • Abstract ISPR8-2521 – A7.02 Rehabilitation Addressing to Specific Issues – Spasticity Management, Exhibition Area, 9th–12th July
    • Repeated AbobotulinumtoxinA Injections Benefit Walking Speed, Step Length and Cadence in Adults with Spastic Hemiparesis due to Stroke or Traumatic Brain Injury
    • Presenting author: Alberto Esquenazi
  • Abstract ISPR8-2529 – A7.02 Rehabilitation Addressing to Specific Issues – Spasticity Management, Exhibition Area, 9th–12th July
    • Efficacy and Safety of Early Use of AbobotulinumtoxinA in Adults with Post-Stroke Spasticity: Results from the ONTIME and ABCDE-S Studies
    • Presenting author: Raymond Rosales
  • Abstract ISPR8-2543 – A7.02 Rehabilitation Addressing to Specific Issues – Spasticity Management, Exhibition Area, 9th–12th July
    • Treatment Frequency for Long-Term Efficacy of AbobotulinumtoxinA Injections: a Phase 3 Study in Patients with Upper Limb Spasticity Following Stroke or Traumatic Brain Injury
    • Presenting author: Jean-Michel Gracies
  • Abstract ISPR8-2546 – A7.02 Rehabilitation Addressing to Specific Issues – Spasticity Management, Exhibition Area, 9th–12th July
    • When Can Maximal Efficacy be Expected with Repeated Botulinum Toxin Injections in Upper Limb Spastic Paresis? An Exploratory Statistical Analysis
    • Presenting author: Jean-Michel Gracies
  • Abstract ISPR8-2547 – A7.02 Rehabilitation Addressing to Specific Issues – Spasticity Management, Exhibition Area, 9th–12th July
    • AbobotulinumtoxinA Injections in Shoulder Muscles: Results from a Real World (ULIS-II) and Phase 3 (AUL) Studies
    • Presenting author: Francois Constant Boyer
  • Abstract ISPR8-2557 – A7.02 Rehabilitation Addressing to Specific Issues – Spasticity Management, Exhibition Area, 9th–12th July
    • Treatment Frequency for Long-Term Efficacy of AbobotulinumtoxinA Injections: a Phase 3 Study in Patients with Lower Limb Spasticity Following Stroke or Traumatic Brain Injury
    • Presenting author: Prof Jean-Michel Gracies
  • Abstract ISPR8-2654 – A2.08 Musculoskeletal Conditions – Miscellanous, Exhibition Area, 9th–12th July
    • Results from the First Recombinant Botulinum Toxin (BoNT) Ever to Enter Clinical Development. Outcomes of a First-in-Human Study with Recombinant BoNT/E (SXN102308)
    • Presenting author: Laurent Pons

About Dysport®

Dysport® is an injectable form of a botulinum neurotoxin type A product, which is a substance derived from Clostridium bacteria producing BoNT-A that inhibits the effective transmission of nerve impulses and thereby reduces muscular contractions. It is supplied as a lyophilized powder. As of 31 December 2017, Dysport® had marketing authorization in more than 85 countries.

About Spasticity

Spasticity is a condition in which there is an abnormal increase in muscle tone or stiffness in one or more muscles, which might interfere with movement. Spasticity is usually caused by damage to nerve pathways in the brain or spinal cord that control muscle movement, and may occur in association with cerebral palsy, spinal cord injury, multiple sclerosis, stroke, and brain or head trauma.3 In adults, approximately one in three stroke patients, one in three patients with spinal cord injury, one in six patients with traumatic brain injury, and two in three patients with MS will develop lower limb spasticity.1,2

INDICATIONS AND IMPORTANT SAFETY INFORMATION

Dysport® is approved for the treatment of adult upper and lower limb spasticity, pediatric lower limb spasticity and cervical dystonia (referred to spasmodic torticollis in some markets) in many international markets including France and the United States of America. Please refer to national labelling for details of the locally approved prescribing information in each of these indications.

Adverse effects resulting from the distribution of the effects of the toxin to sites remote from the site of administration have been reported. Patients treated with therapeutic doses may present with excessive muscle weakness. The risk of occurrence of such undesirable effects may be reduced by using the lowest effective dose possible and by not exceeding the maximum recommended dose.

Very rare cases of death, occasionally in the context of dysphagia, pneumopathy (including but not limited to dyspnoea, respiratory failure, respiratory arrest) and/or in patients with significant asthenia have been reported following treatment with botulinum toxin A or B. Patients with disorders resulting in defective neuromuscular transmission, difficulty in swallowing or breathing are more at risk of experiencing these effects. In these patients, treatment must be administered under the control of a specialist and only if the benefit of treatment outweighs the risk. Dysport® should be administered with caution to patients with pre-existing swallowing or breathing problems as these can worsen following the distribution of the effect of toxin into the relevant muscles. Aspiration has occurred in rare cases and is a risk when treating patients who have a chronic respiratory disorder. Dysport® should only be used with caution and under close medical supervision in patients with clinical or sub-clinical evidence of marked defective neuro-muscular transmission (e.g. myasthenia gravis). Such patients may have an increased sensitivity to agents such as Dysport®, which may result in excessive muscle weakness. Caution should be exercised when treating adult patients, especially the elderly, with focal spasticity affecting the lower limbs, who may be at increased risk of fall. In placebo-controlled clinical studies where patients were treated for lower limb spasticity, 6.3% and 3.7% of patients experienced a fall in the Dysport® and placebo groups, respectively. The recommended posology and frequency of administration for Dysport® must not be exceeded. Patients and their care-givers must be warned of the necessity to seek immediate medical treatment in case of problems with swallowing, speech or respiratory problems. For the treatment of spasticity in children, Dysport® should only be used in children 2 years of age or over. As with any intramuscular injection, Dysport® should only be used where strictly necessary in patients with prolonged bleeding times, or infection/inflammation at the proposed site(s) of injection. Dysport® should only be used to treat a single patient, during a single session. Any unused product remaining should be disposed of in accordance with Special Precautions for Disposal and Handling. Specific precautions must be taken during the preparation and administration of the product and the inactivation and disposal of any unused reconstituted solution. This product contains a small amount of human albumin. The risk of transmission of viral infection cannot be excluded with absolute certainty following the use of human blood or blood products.”

References:
1. Martin A, et al. Epidemiological, humanistic, and economic burden of illness of lower limb spasticity in adults: a systematic review. Neuropsychiatric Disease and Treatment. 2014; 10 (111-122)
2. Sköld A, et al. Spasticity after traumatic spinal cord injury: nature, severity, and location. Archives of Physical Medicine and Rehabilitation. 1999; 80 (1548-57)
3. National Institute of Neurological Disorders and Stroke. Spasticity Information Page. https://www.ninds.nih.gov/Disorders/All-Disorders/Spasticity-Information-Page Accessed May 16, 2017.

About Ipsen

Ipsen is a global biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Diseases. Its commitment to Oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over €1.9 billion in 2017, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen's R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,400 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit www.ipsen.com.

Forward Looking Statement

The forward-looking statements, objectives and targets contained herein are based on the Group’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words "believes", "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements, including the Group’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group’s activities and financial results. The Group cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group’s partners could generate lower revenues than expected. Such situations could have a negative impact on the Group’s business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to the Group’s 2017 Registration Document available on its website (www.ipsen.com).

Contact information

For further information :
Ipsen
Media
Ian Weatherhead, +44 (0) 1753 627733
Vice President, Corporate External Communications
ian.weatherhead@ipsen.com
or
Brigitte Le Guennec, +33 (0)1 58 33 51 17
Senior Manager, Global External Communications
brigitte.le.guennec@ipsen.com
or
Financial Community
Eugenia Litz, +44 (0) 1753 627721
Vice President, Investor Relations
eugenia.litz@ipsen.com
or
Myriam Koutchinsky, +33 (0)1 58 33 51 04
Investor Relations Manager
myriam.koutchinsky@ipsen.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Schlumberger Announces Fourth-Quarter and Full-Year 2018 Results Conference Call16.11.2018 18:00Pressemelding

Schlumberger Limited (NYSE:SLB) will hold a conference call on January 18, 2019 to discuss the results for the fourth quarter and full year ending December 31, 2018. The conference call is scheduled to begin at 8:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 288-8967 within North America or +1 (612) 333-4911 outside of North America approximately 10 minutes prior to the start of the call, and ask for the “Schlumberger Earnings Conference Call.” A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until February 18, 2019, and can be accessed by dialing +1 (800)

Visa Strengthens Commitment to Growing Digital Payments in India16.11.2018 14:33Pressemelding

Visa (NYSE: V) today announced a minority investment in BillDesk, a leading platform for online payments and bill payments in India. Visa’s investment and collaboration will help BillDesk develop new product lines for its payments and loyalty businesses and also expand its footprint into other geographies. The investment will be subject to necessary statutory approvals and is expected to have no direct bearing on Visa’s existing Indian business. “As a leading payments player in India, BillDesk has been a long time business partner to Visa. Having worked with BillDesk’s founders over the years, the Visa leadership has been consistently impressed with their vision, market knowledge and execution capabilities, as well as alignment on values. This investment further reinforces our long-term commitment to India’s digital payments growth story,” said Asia Pacific regional president, Chris Clark. “We are truly excited by this investment from the world's largest global payment network, Visa. W

Guidewire Enhances PartnerConnect Consulting Program with Addition of Product and Regional Specializations16.11.2018 13:55Pressemelding

Guidewire Software, Inc. (NYSE: GWRE), provider of the industry platform Property and Casualty (P&C) insurers rely upon, today announced the addition of specializations to its PartnerConnect Consulting program. Specializations have been added to aid insurance companies in selecting the best partner to lead or staff their Guidewire projects. Guidewire unveiled new specializations, including two which have been successfully piloted earlier this year. “Our customers will now have more clarity and information as to which partners have the proven capabilities in their chosen product and region,” said Lisa Walsh, vice president, Alliances, Guidewire Software. “Adding these specializations will also allow us to have more insight into a partner’s performance and competencies.” To earn a specialization, partners need to demonstrate skills, knowledge, and competency in a specific Guidewire product or solution by certifying staff at multiple levels (specialist and professional) through Guidewire’

Janssen receives positive CHMP opinion for ERLEADA™ (apalutamide) for patients with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease16.11.2018 13:15Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for apalutamide, a next generation oral androgen receptor inhibitor for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.2 The CHMP’s positive opinion will now be reviewed by the European Commission (EC), which has the authority to grant approval for the use of apalutamide. The CHMP’s positive opinion is based on data from the pivotal SPARTAN Phase 3 clinical study which assessed the safety and efficacy of apalutamide versus placebo in patients with nmCRPC who have a rapidly rising prostate specific antigen (PSA) level despite receiving continuous androgen deprivation therapy (ADT). The SPARTAN clinical study showed that apalutamide, when added to ADT, significantly reduced the risk

Vertex Receives European CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease16.11.2018 12:57Pressemelding

Vertex Pharmaceuticals (Europe) Limited today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ORKAMBI® (lumacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) aged 2 to 5 years old who have two copies of the F508del mutation, the most common form of the disease. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, lumacaftor/ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF for patients aged 2 to 5 years old who have two copies of the F508del mutation. “Cystic fibrosis is a chronic, progressive disease and it is important to treat early to ensure the best possible outcomes for patients,” said Reshma Kewalramani, MD, Executive Vice President, Global Medicines Development and Medical Affairs and Chief Medical Officer at Vertex. “Today’s announcement brings us one step cl

Dimension Data Global Delivery Centre (GDC) in Prague wins the ABSL 2018 Diamond Award for Business Innovation16.11.2018 08:00Pressemelding

Dimension Data, the USD 8 billion global technology integrator and managed services provider, today announced that its Global Delivery Centre (GDC) in Prague has won the 2018 ABSL Diamond award for Business Innovation. The main purpose of this centre is to provide innovative, global service delivery capabilities and deep technical expertise to support our clients. The ABSL Diamond awards recognise companies that implement innovative projects, enhancing their business and strengthening the position of the business services sector. Every year, the aim is to identify successful activities in this sector and promote best practices, ultimately encouraging and inspiring others to follow suit. The ABSL celebrates initiatives that push business services forward and stand out as exemplary projects. Bill Padfield, Group Chief Operating Officer for Transformation and Services at Dimension Data, said: “Winning another award for our Support Services is a fantastic achievement. This time the ABSL Di